Skip to content

Categories: cancer research

Efficacy of Esophageal Cancer Postoperative Adjuvant Treatment, Peptide Vaccine Treatment, Elucidated 5-year Survival Rate Approx. Doubled for Esophageal Cancer Patients - Kindai University

Efficacy of Esophageal Cancer Postoperative Adjuvant Treatment, Peptide Vaccine Treatment, Elucidated 5-year Survival Rate Approx. Doubled for Esophageal Cancer Patients - Kindai University

Kindai University’s Faculty of Medicine has, in a world first, shown the efficacy of cancer-specific vaccine therapy as a postoperative adjuvant therapy in a phase 2 clinical trial. Administration of cancer-specific vaccine therapy roughly doubled the 5-year survival rate of advanced esophageal cancer patients. Vaccine therapy amplifying CTL2 is expected to help validate peptide vaccine therapy.

Welcome to Japan University News!

“Japan University News” is an English-language news portal that provides an outlet for the latest news of Japanese Universities for a global audience. It provides an overview of the unique culture, prominent research and contributions to the global society of Japanese Universities for international media, stakeholders and other interested parties.

Japan University News
Japan University News